News – Page 1133 – Endpoints News

Another biotech games the system, and everyone gets to pay for the fallout

9 years ago

Intercept ‘lowers the bar’ on its pivotal PhIII OCA study for NASH

9 years ago

Seattle Genetics grabs Immunomedics’ tumor drug in $2B deal, shooting for a quick OK

9 years ago

Daiichi Sankyo shutters another R&D center in an ongoing global overhaul

9 years ago

Neurocrine adds a Parkinson’s drug to its late-stage pipeline in $145M deal

9 years ago

Marathon's cheap, old steroid breezes through the FDA for Duchenne MD, and gets priced at $89K

9 years ago

Biotech voices: Allergan CEO Saunders isn’t slowing down on a brisk pace of biotech dealmaking

9 years ago

Tetraphase CEO touts troubled antibiotic’s peak sales potential; Copenhagen wants to host the EMA

9 years ago

Playing catch-up, Regeneron and Sanofi push ahead on pivotal PD-1 cancer studies

9 years ago

Acorda preps FDA filing after Parkinson’s drug hits the primary endpoint in PhIII

9 years ago

After winning an early deal on XO1, the virtual biotech gang gets back together for SuperX

9 years ago

Sanofi, Regeneron win a crucial stay of execution on Praluent

9 years ago

Bayer, J&J wrap positive PhIII cardio study for Xarelto early, looking to beef up its market

9 years ago

The next PARP M&A deal? Tesaro shares surge on latest buzz about a buyout

9 years ago

Lysogene raises $25M in Paris IPO; Chan Zuckerberg Biohub starts handing out $50M

9 years ago

After clearing an FDA hurdle, Amgen wins an FDA OK on CKD drug Parsabiv

9 years ago

Two friends and biotech colleagues with a passion for insider info - feds charge Merrimack staffer

9 years ago

As hep C revenue disintegrates, pressure keeps growing on Gilead to do deals

9 years ago

Lundbeck reads last rites on another failed PhIII Alzheimer’s program

9 years ago

White House: Trump remains committed to Medicare drug price negotiations

9 years ago

GW touts positive survival benefit in small brain cancer study; Ablynx files for ultra-rare disease drug OK

9 years ago

A swarm of top biotech execs protest against Trump’s travel ban, saying it threatens the entire industry

9 years ago

A better gene therapy vector out of Harvard is credited with restoring normal hearing in mice

9 years ago

Serono spinout grabs a $31M round for a pair of proof-of-concept Parkinson’s trials

9 years ago

First page Previous page 1130 1131 113211331134 1135 1136 Next page Last page